In this Business Breakdown, David Barbato and Sergio Heiber sit down with NeurAxis’s (NRXS) CEO Brian Carrico. The company was originally profiled by Sergio Heiber on August 18, 2024, at $3.14 USD per share.

This discussion took place live on February 18th, 2026, on the MicroCapClub Community. Join MicroCapClub and unlock the ability to listen and participate live in these discussions - https://microcapclub.com/join-now/

In this conversation, Brian Carrico, CEO of Neuroaxis, discusses the company's growth, the significance of the Category One CPT code, and the current market position. He highlights the importance of strong data for insurance coverage and reimbursement, the focus on pediatric healthcare, and the expansion into the VA market. The discussion also covers the company's treatment mechanisms, ongoing clinical trials, and strategies for scaling operations. Audience questions provide further insights into insurance negotiations and market opportunities.

✉️ Share your feedback - david@microcapclub.com

✉️ David’s X (Twitter) - https://x.com/Valuehunte

Chapters

00:00 Introduction to Neuroxys and Brian Carrico's Background

04:51 Understanding Neuromodulation and Its Applications

10:57 Market Potential and Addressable Market

14:22 Research and Development: Clinical Trials and Data

18:17 Go-to-Market Strategy and Scaling Challenges

21:20 Financial Overview and Future Projections

26:39 Insurance Coverage and Market Expansion

30:36 Veterans Affairs Market and Initial Feedback

33:52 Focus on Pediatric Market and Future Directions

38:53 Understanding the VA Hospital System

41:41 Reimbursement and Relative Value Units (RVUs)

43:52 Capital Needs and Financial Strategy

44:12 Market Opportunities and Misconceptions

46:24 Insurance Assessment Timing and Coverage

47:57 Regulatory Considerations and FDA Interactions

49:25 Patient Treatment Protocols and Data Availability

50:57 Manufacturing and Scaling Challenges

51:18 Centers of Excellence and Patient Care

52:24 Insurance Coverage and Market Dynamics

53:31 Key Performance Indicators and Future Planning

Disclaimer: All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.

NeurAxis, Inc. (NRXS): Growth-Stage Medtech